These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 21876122

  • 1. Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
    Roy L, Tomowiak C, Guilhot F.
    Blood; 2011 Nov 10; 118(19):5096-8. PubMed ID: 21876122
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
    Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J.
    Blood; 2011 Feb 10; 117(6):1822-7. PubMed ID: 21030554
    [Abstract] [Full Text] [Related]

  • 6. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM.
    Leukemia; 2008 Jun 10; 22(6):1200-6. PubMed ID: 18401416
    [Abstract] [Full Text] [Related]

  • 7. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, Vela-Ojeda J, Silver RT, Khoury HJ, Müller MC, Lambert A, Matloub Y, Hochhaus A.
    Haematologica; 2010 Feb 10; 95(2):232-40. PubMed ID: 20139391
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
    Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ.
    Blood; 2012 Nov 08; 120(19):3898-905. PubMed ID: 22915637
    [Abstract] [Full Text] [Related]

  • 9. Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
    Kantarjian H.
    Clin Adv Hematol Oncol; 2008 Nov 08; 6(11):797-9. PubMed ID: 19194361
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A, Müller MC, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A, Hughes TP.
    Leukemia; 2009 Sep 08; 23(9):1628-33. PubMed ID: 19641527
    [Abstract] [Full Text] [Related]

  • 12. Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
    Cannella L, Loglisci G, Nanni M, De Cuia MR, Colafigli G, Salaroli A, Serrao A, Alimena G, Breccia M.
    Leuk Lymphoma; 2012 Mar 08; 53(3):497-8. PubMed ID: 21854086
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD, Lee H, Kamel-Reid S, Lipton JH.
    Br J Haematol; 2013 Mar 08; 160(5):630-9. PubMed ID: 23278256
    [Abstract] [Full Text] [Related]

  • 15. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
    Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE.
    Am J Hematol; 2013 Dec 08; 88(12):1024-9. PubMed ID: 23913852
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia.
    Cortes JE.
    J Clin Oncol; 2012 Jan 20; 30(3):223-4. PubMed ID: 22184376
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chronic myeloid leukemia: advances in diagnosis and management.
    Noronha S, Sawyer S.
    JAAPA; 2013 Feb 20; 26(2):26-9. PubMed ID: 23409382
    [No Abstract] [Full Text] [Related]

  • 20. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
    Jabbour E, Cortes J, Nazha A, O'Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H.
    Blood; 2012 May 10; 119(19):4524-6. PubMed ID: 22431574
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.